Novo Holdings A/S

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

Retrieved on: 
Wednesday, March 13, 2024
SVB Securities, Stifel, Common stock, Novo Holdings A/S, Sale, Public expenditure, Prospectus, Therapy, Security (finance)

Lexeo sold 6,278,905 shares of its common stock (“Common Stock”) in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), at a sale price equal to $15.13 per share.

Key Points: 
  • Lexeo sold 6,278,905 shares of its common stock (“Common Stock”) in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), at a sale price equal to $15.13 per share.
  • Lexeo intends to use net proceeds from the financing to fund advancement of ongoing clinical stage programs, and for working capital and general corporate purposes.
  • The proceeds from this financing, combined with current cash, cash equivalents and marketable securities, are expected to fund operating and capital expenditures into 2027.
  • Any offering of the shares sold in the private placement under the Resale Registration Statement will only be made by means of a prospectus.

Obsidian Therapeutics Announces Oversubscribed $160.5 Million Series C Financing to Drive OBX-115 Clinical Development

Retrieved on: 
Wednesday, April 3, 2024
Biotechnology, Health, Genetics, Clinical Trials, Oncology, Janus, Growth, Novo Holdings A/S, NSCLC, TIL, Patient, Wellington Management Company, Paradigm, Foresite Capital, Bristol Myers Squibb, Lung cancer, Doctor of Philosophy, Therapy, Melanoma, Investment, Atlas Venture, Pharmaceutical industry

Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a significantly oversubscribed $160.5 million Series C financing with a top-tier syndicate of life science investors led by new investor, Wellington Management.

Key Points: 
  • Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a significantly oversubscribed $160.5 million Series C financing with a top-tier syndicate of life science investors led by new investor, Wellington Management.
  • Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC).
  • The Company is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.
  • “This financing provides funding through key clinical readouts in melanoma and is the catalyst to continue expanding OBX-115 into NSCLC, where there is significant potential and high unmet need.”

Trinity Hunt Announces Formation of Supreme Group and Appoints Tom Donnelly CEO

Retrieved on: 
Wednesday, March 20, 2024
Professional Services, Marketing, Health, Digital Marketing, Communications, Finance, General Health, Knowledge, MKG, Growth, Medicine, Court Square Capital Partners, Novo Holdings A/S, Donnelly (surname), Evoke, Advertising, Pharmaceutical industry

Supreme Group was formed following Trinity Hunt Partners ’ majority investment in Supreme Optimization , a leading life science-focused digital agency providing best-in-class performance digital marketing services to the life science industry.

Key Points: 
  • Supreme Group was formed following Trinity Hunt Partners ’ majority investment in Supreme Optimization , a leading life science-focused digital agency providing best-in-class performance digital marketing services to the life science industry.
  • “Tom’s extensive experience leading and growing healthcare marketing and communications businesses makes him the ideal leader for Supreme Group,” said Mike Steindorf, partner at Trinity Hunt.
  • “I am excited to join Supreme Group and look forward to making an impact in this dynamic and growing space,” said Donnelly.
  • “Already during my short time working with Trinity Hunt and the team at Supreme Optimization, we have made tremendous progress in building the Supreme Group platform.”

Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing

Retrieved on: 
Monday, March 11, 2024
Prospectus, Novo Holdings A/S, Stifel, J. P. Morgan, Common stock, Sale, SVB Securities, Therapy, Public expenditure, Security (finance)

Lexeo anticipates the gross proceeds from the private placement to be approximately $95.0 million, before deducting any offering related expenses.

Key Points: 
  • Lexeo anticipates the gross proceeds from the private placement to be approximately $95.0 million, before deducting any offering related expenses.
  • The financing is expected to close on March 13, 2024, subject to customary closing conditions.
  • Lexeo intends to use net proceeds from the financing to fund advancement of ongoing clinical stage programs, and for working capital and general corporate purposes.
  • The proceeds from this financing, combined with current cash, cash equivalents and marketable securities are expected to fund Lexeo’s operating and capital expenditures into 2027.

Novo Nordisk Foundation awarded more than DKK 9.1 billion for purposes benefitting society in 2023

Retrieved on: 
Wednesday, March 6, 2024
Novo Nordisk Foundation, Research, Biotechnology, DKK, Antimalarial medication, Education, Investment, Food, Partnership, NIVI, Vaccine, University, Health, Climate change, Novo Holdings A/S, CO2, Protein, Tuberculosis, Science, Agriculture, Bill, Human

In 2023, the Foundation awarded more than DKK 9.1 billion, in philanthropic grants and investments, and supported a total of 751 new projects.

Key Points: 
  • In 2023, the Foundation awarded more than DKK 9.1 billion, in philanthropic grants and investments, and supported a total of 751 new projects.
  • One of its largest mission-driven initiatives in 2023 was the Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI), a research and vaccine development initiative launched in partnership with the University of Copenhagen.
  • The DKK 9.1 billion awarded in 2023 marks an increase in grant giving from previous years.
  • The Novo Nordisk Foundation Cellerator, a world-class facility for developing and upscaling cell therapies for testing in humans.

Novo Nordisk Foundation awarded more than DKK 9.1 billion for purposes benefitting society in 2023

Retrieved on: 
Wednesday, March 6, 2024
Novo Nordisk Foundation, Research, Biotechnology, DKK, Antimalarial medication, Education, Investment, Food, Partnership, NIVI, Vaccine, University, Health, Climate change, Novo Holdings A/S, CO2, Protein, Tuberculosis, Science, Agriculture, Bill, Human

In 2023, the Foundation awarded more than DKK 9.1 billion, in philanthropic grants and investments, and supported a total of 751 new projects.

Key Points: 
  • In 2023, the Foundation awarded more than DKK 9.1 billion, in philanthropic grants and investments, and supported a total of 751 new projects.
  • One of its largest mission-driven initiatives in 2023 was the Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI), a research and vaccine development initiative launched in partnership with the University of Copenhagen.
  • The DKK 9.1 billion awarded in 2023 marks an increase in grant giving from previous years.
  • The Novo Nordisk Foundation Cellerator, a world-class facility for developing and upscaling cell therapies for testing in humans.

Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock

Retrieved on: 
Friday, January 19, 2024
Biotechnology, Pharmaceutical, Health, Cardiology, Janus, Citadel, Myopathy, Patient, Therapy, Research, SVB Securities, OrbiMed, Edgewise, Prospectus, Novo Holdings A/S, Form, Sale, Becker muscular dystrophy, ATTN:, Montgomery Street, Attention, Telephone, State Street

Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 21,818,182 shares of its common stock at an offering price of $11.00 per share.

Key Points: 
  • Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 21,818,182 shares of its common stock at an offering price of $11.00 per share.
  • Edgewise anticipates gross proceeds from the offering to be approximately $240 million, before deducting underwriting discounts and commissions and offering expenses.
  • The closing of the offering is expected to occur on January 23, 2024, subject to the satisfaction of customary closing conditions.
  • A prospectus supplement and accompanying prospectus relating to the offering will also be filed with the SEC.

Paratek Pharmaceuticals Announces Promotion of Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer and Christopher Bostrom to Chief Financial Officer

Retrieved on: 
Tuesday, January 16, 2024
Record, Light, Patient, General counsel, Corporation, Morgan Lewis, Stonehill College, Teva Pharmaceuticals, Executive Counsel Limited, University, Novo Holdings A/S, Babson College, Public, Dartmouth College, MBA, Acquisition, Shire (pharmaceutical company), Bachelor of Science, Virginia School for Girls, Biogen, Marketing, Growth, Management

Paratek promoted Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer and Christopher Bostrom to Chief Financial Officer.

Key Points: 
  • Paratek promoted Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer and Christopher Bostrom to Chief Financial Officer.
  • “It has been inspiring to help build an organization that is committed to excellence and upholding the highest ethical standards.
  • Bostrom joined Paratek in March 2016 and has over 20 years of financial, strategic and operational experience.
  • Bostrom received his Bachelor of Science in business administration from Stonehill College and an MBA from Babson College.

Claris Bio Emerges From Stealth With a New Investor and Prepares for Next Development Stage With Late-Stage Data Expected in 1H24

Retrieved on: 
Thursday, January 4, 2024
Janus, Commercialization, OD, Drug development, Completeness, CMO, Hepatocyte growth factor, Master of Science, Novo Holdings A/S, Ear, MD, Neurotrophic factors, Nerve, Mass, Burns (surname), Mouth ulcer, Perforation, Ulcer, Series, Scar, MPH, Patient, NK, Medical imaging

Claris, initially funded in 2020, is developing recombinant human variant hepatocyte growth factor, dHGF, to accelerate and improve the quality of corneal healing in patients with corneal eye disease.

Key Points: 
  • Claris, initially funded in 2020, is developing recombinant human variant hepatocyte growth factor, dHGF, to accelerate and improve the quality of corneal healing in patients with corneal eye disease.
  • Oremepermin-α is epitheliotropic, neurotrophic, anti-inflammatory, and anti-fibrotic, suggesting it could be an efficacious and safe option to treat many current unmet needs in diseases of the cornea.
  • Claris expects to complete enrollment in its late-stage multi-center, randomized, double-masked, vehicle-controlled, parallel-group study, with a data readout expected in 1H2024.
  • Additional indications of interest that are being actively pursued by Claris, supported by preclinical and clinical data, include limbal stem cell deficiency and pre-existing corneal scar.

NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing

Retrieved on: 
Wednesday, November 15, 2023
Spinal muscular atrophy, Acetylcholine receptor, Investment, Patient, Myasthenia gravis, Novo Holdings A/S, Therapy, Charcot–Marie–Tooth disease, MuSK protein, NMD, Growth, Pharma, Pharmaceutical industry, Fine chemical

The financing was led by current investor Jeito Capital and includes investments from other current NMD Pharma investors: Novo Holdings, Lundbeckfonden BioCapital, INKEF Capital, and the Roche Venture Fund.

Key Points: 
  • The financing was led by current investor Jeito Capital and includes investments from other current NMD Pharma investors: Novo Holdings, Lundbeckfonden BioCapital, INKEF Capital, and the Roche Venture Fund.
  • NMD Pharma is developing first-in-class small molecule inhibitors of the skeletal muscle specific chloride ion channel (ClC-1) to enhance neuromuscular transmission with the potential to restore muscle function in a range of rare neuromuscular diseases.
  • Proceeds from the financing will be used to complete three Phase 2 studies with NMD670, the Company’s lead ClC-1 inhibitor.
  • Furthermore, NMD Pharma will continue to expand its pipeline of ClC-1 inhibitor molecules and pursue undisclosed targets for the treatment of other neuromuscular diseases.